Literature DB >> 18230833

Reduced quality of life in patients with head-and-neck paragangliomas.

B Havekes1, A A van der Klaauw, H C Hoftijzer, J C Jansen, A G L van der Mey, A H J T Vriends, J W A Smit, J A Romijn, E P M Corssmit.   

Abstract

OBJECTIVE: The objective of this study was to assess the quality of life (QoL) in patients with head-and-neck paragangliomas ('glomus tumors').
DESIGN: We conducted a case-control study.
METHODS: We assessed QoL in 82 patients with head-and-neck paragangliomas using four validated health-related questionnaires: Hospital Anxiety and Depression Scale, Multidimensional Fatigue Index (MFI-20), Short Form-36 (SF-36), and Nottingham Health Profile (NHP). Patient outcomes were compared with controls provided by the patients and with a large age- and sex-adjusted control group.
RESULTS: The QoL scores in the paraganglioma patients were significantly reduced in 12 out of the 21 subscales compared with own controls, and in 18 out of the 21 subscales compared with age- and sex-adjusted values derived from the previous studies. In the MFI-20 questionnaire, patients reported more general fatigue, physical fatigue, mental fatigue, and a reduction in activity and motivation. The scores in the NHP showed a difference in energy, emotional reaction, and social isolation. General health perception, pain, and physical functioning were reported to be worse in the paraganglioma patients on the SF-36 scale. Although anxiety and depression did not reveal any significant differences between patients and their own controls, an increased score on both anxiety and depression was seen when compared with the extended control group. Especially, dysphonia contributes to a reduced QoL.
CONCLUSION: QoL is considerably reduced in patients with head-and-neck paragangliomas.

Entities:  

Mesh:

Year:  2008        PMID: 18230833     DOI: 10.1530/EJE-07-0464

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  8 in total

1.  Normal life expectancy for paraganglioma patients: a 50-year-old cohort revisited.

Authors:  Jeanette de Flines; Jeroen Jansen; Reinier Elders; Maaike Siemers; Annette Vriends; Frederik Hes; Jean-Pierre Bayley; Andel van der Mey; Eleonora Corssmit
Journal:  Skull Base       Date:  2011-11

2.  Glomus caroticum tumor as rare cause of recurrent syncope.

Authors:  Michael Schmid; Dieter Raithel; Eckhart G Hahn; Werner G Daniel; Raithel Martin
Journal:  Clin Res Cardiol       Date:  2012-02-25       Impact factor: 5.460

3.  Glomus tympanicum.

Authors:  V R Appannan; M K Md Daud
Journal:  Malays Fam Physician       Date:  2018-04-30

Review 4.  Current approaches and recent developments in the management of head and neck paragangliomas.

Authors:  David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak
Journal:  Endocr Rev       Date:  2014-07-17       Impact factor: 19.871

5.  Clinicopathological analysis of paraganglioma with literature review.

Authors:  Ning Feng; Wen-Yan Zhang; Xiao-Ting Wu
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

6.  Head-and-neck paragangliomas are associated with sleep-related complaints, especially in the presence of carotid body tumors.

Authors:  Bas Havekes; Florine Kastelein; Agatha A van der Klaauw; Nicolette van Duinen; Jeroen C Jansen; Jan W A Smit; Klaas W van Kralingen; Annette H J T Vriends; Johannes A Romijn; Eleonora P M Corssmit
Journal:  Sleep Breath       Date:  2011-05-27       Impact factor: 2.816

Review 7.  Giant carotid chemodectoma treated with a combination of surgery and CyberKnife radiotherapy: a case report and review of the literature.

Authors:  José M López-Arcas; César M Colmenero; Roberto Martínez; Fátima Martín-Hernán; Beatriz Ruiz-Sánchez; Juan Manuel Aragoneses
Journal:  J Med Case Rep       Date:  2022-02-25

8.  Post-Embolization Excision of Glomus Tympanicum: A Case Report.

Authors:  Girija Ghate; Aastha Bhatnagar; Sabreena Mukhtar
Journal:  Cureus       Date:  2022-01-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.